198 related articles for article (PubMed ID: 12747884)
1. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.
Groet J; McElwaine S; Spinelli M; Rinaldi A; Burtscher I; Mulligan C; Mensah A; Cavani S; Dagna-Bricarelli F; Basso G; Cotter FE; Nizetic D
Lancet; 2003 May; 361(9369):1617-20. PubMed ID: 12747884
[TBL] [Abstract][Full Text] [Related]
2. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
3. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
Bercovich D; Ganmore I; Scott LM; Wainreb G; Birger Y; Elimelech A; Shochat C; Cazzaniga G; Biondi A; Basso G; Cario G; Schrappe M; Stanulla M; Strehl S; Haas OA; Mann G; Binder V; Borkhardt A; Kempski H; Trka J; Bielorei B; Avigad S; Stark B; Smith O; Dastugue N; Bourquin JP; Tal NB; Green AR; Izraeli S
Lancet; 2008 Oct; 372(9648):1484-92. PubMed ID: 18805579
[TBL] [Abstract][Full Text] [Related]
4. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome.
Ito E; Kasai M; Hayashi Y; Toki T; Arai K; Yokoyama S; Kato K; Tachibana N; Yamamoto M; Yokoyama M
Br J Haematol; 1995 Jul; 90(3):607-14. PubMed ID: 7647001
[TBL] [Abstract][Full Text] [Related]
5. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
6. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.
Hitzler JK; Cheung J; Li Y; Scherer SW; Zipursky A
Blood; 2003 Jun; 101(11):4301-4. PubMed ID: 12586620
[TBL] [Abstract][Full Text] [Related]
7. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.
Gurbuxani S; Vyas P; Crispino JD
Blood; 2004 Jan; 103(2):399-406. PubMed ID: 14512321
[TBL] [Abstract][Full Text] [Related]
8. Origins of leukaemia in children with Down syndrome.
Hitzler JK; Zipursky A
Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
[TBL] [Abstract][Full Text] [Related]
9. Natural history of GATA1 mutations in Down syndrome.
Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
[TBL] [Abstract][Full Text] [Related]
10. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
[TBL] [Abstract][Full Text] [Related]
11. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
Garnett C; Cruz Hernandez D; Vyas P
IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
[TBL] [Abstract][Full Text] [Related]
12. GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
Lum SH; Choong SS; Krishnan S; Mohamed Z; Ariffin H
Singapore Med J; 2016 Jun; 57(6):320-4. PubMed ID: 27353457
[TBL] [Abstract][Full Text] [Related]
13. [GATA1 analysis in myeloproliferative disorders associated to trisomy 21].
Fuster Soler JL; Norton A; Galera Miñarro A; Bermúdez Cortés M; Llinares Riestra ME; Ortuño Giner F
An Pediatr (Barc); 2011 Jan; 74(1):31-7. PubMed ID: 20870473
[TBL] [Abstract][Full Text] [Related]
14. "TAM"ing of the shrew-challenges in the diagnosis of Neonatal leukemia with Down's syndrome -A case report with literature review.
Manohar S; Jayakumar N
Indian J Pathol Microbiol; 2022; 65(3):699-701. PubMed ID: 35900507
[TBL] [Abstract][Full Text] [Related]
15. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.
Alford KA; Reinhardt K; Garnett C; Norton A; Böhmer K; von Neuhoff C; Kolenova A; Marchi E; Klusmann JH; Roberts I; Hasle H; Reinhardt D; Vyas P;
Blood; 2011 Aug; 118(8):2222-38. PubMed ID: 21715302
[TBL] [Abstract][Full Text] [Related]
16. Mutation characterization in the GATA-1 gene in patients with Down's Syndrome diagnosed with transient abnormal myelopoiesis or acute megakaryoblastic leukemia.
Mansini AP; Rubio PL; Rossi JG; Gallego MS; Medina A; Zubizarreta PA; Felice MS; Alonso CN
Arch Argent Pediatr; 2013 Dec; 111(6):532-6. PubMed ID: 24196768
[TBL] [Abstract][Full Text] [Related]
17. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
18. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
Mundschau G; Gurbuxani S; Gamis AS; Greene ME; Arceci RJ; Crispino JD
Blood; 2003 Jun; 101(11):4298-300. PubMed ID: 12560215
[TBL] [Abstract][Full Text] [Related]
19. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
Crispino JD
Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
[TBL] [Abstract][Full Text] [Related]
20. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
